BR112018068538A2 - composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. - Google Patents
composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno.Info
- Publication number
- BR112018068538A2 BR112018068538A2 BR112018068538-0A BR112018068538A BR112018068538A2 BR 112018068538 A2 BR112018068538 A2 BR 112018068538A2 BR 112018068538 A BR112018068538 A BR 112018068538A BR 112018068538 A2 BR112018068538 A2 BR 112018068538A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disease
- prophylaxis
- treatment
- pain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção provê um composto tendo uma ação inibitória de magl e útil como um agente para a profilaxia ou o tratamento de doenças neurodegenerativas (por exemplo, doença de alzheimer, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, lesão cerebral traumática, glaucoma, esclerose múltipla etc.), transtorno de ansiedade, dores (por exemplo, dor inflamatória, dor cancerosa, dor neurogênica etc.), epilepsia, depressão e similares. a presente invenção refere-se a um composto representado pela fórmula (i): em que cada símbolo é como definido na descrição, ou um sal do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-071181 | 2016-03-31 | ||
| JP2016071181 | 2016-03-31 | ||
| PCT/JP2017/014597 WO2017171100A1 (en) | 2016-03-31 | 2017-03-30 | Heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018068538A2 true BR112018068538A2 (pt) | 2019-04-24 |
| BR112018068538B1 BR112018068538B1 (pt) | 2023-12-12 |
Family
ID=58707980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068538-0A BR112018068538B1 (pt) | 2016-03-31 | 2017-03-30 | Composto, medicamento, e, uso de um composto |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10323026B2 (pt) |
| EP (1) | EP3436444B1 (pt) |
| JP (1) | JP6788683B2 (pt) |
| KR (1) | KR102388440B1 (pt) |
| CN (1) | CN109715613B (pt) |
| AR (1) | AR108012A1 (pt) |
| AU (1) | AU2017245125B2 (pt) |
| BR (1) | BR112018068538B1 (pt) |
| CA (1) | CA3019298C (pt) |
| CL (1) | CL2018002777A1 (pt) |
| CO (1) | CO2018009604A2 (pt) |
| DK (1) | DK3436444T3 (pt) |
| EA (1) | EA036637B1 (pt) |
| EC (1) | ECSP18081909A (pt) |
| ES (1) | ES2804580T3 (pt) |
| IL (1) | IL261488B (pt) |
| MX (1) | MX374833B (pt) |
| MY (1) | MY194647A (pt) |
| PE (1) | PE20190409A1 (pt) |
| PH (1) | PH12018502101A1 (pt) |
| PL (1) | PL3436444T3 (pt) |
| SG (1) | SG11201807539UA (pt) |
| TN (1) | TN2018000299A1 (pt) |
| TW (1) | TWI738753B (pt) |
| UA (1) | UA122435C2 (pt) |
| UY (1) | UY37174A (pt) |
| WO (1) | WO2017171100A1 (pt) |
| ZA (1) | ZA201807249B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3438109B1 (en) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| SG11201808270PA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| MA44502A (fr) | 2016-04-01 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US11407715B2 (en) | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| TWI771420B (zh) | 2017-05-22 | 2022-07-21 | 美商健生醫藥公司 | 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物（一） |
| KR20200046061A (ko) | 2017-08-29 | 2020-05-06 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 |
| CA3076477A1 (en) | 2017-09-29 | 2019-04-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| JP7269948B2 (ja) * | 2017-11-28 | 2023-05-09 | エフ． ホフマン－ラ ロシュ アーゲー | 新規複素環式化合物 |
| TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| AU2019322538B2 (en) | 2018-08-13 | 2021-09-30 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| KR20210044217A (ko) * | 2018-08-13 | 2021-04-22 | 에프. 호프만-라 로슈 아게 | 모노아실글리세롤 리파제 저해제로서의 신규 헤테로시클릭 화합물 |
| CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
| BR112022015116A2 (pt) | 2020-02-10 | 2022-09-27 | Janssen Pharmaceutica Nv | Moduladores de monoacilglicerol lipase |
| JP7729831B2 (ja) * | 2020-03-26 | 2025-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン |
| MX2022011901A (es) * | 2020-03-26 | 2023-01-04 | Janssen Pharmaceutica Nv | Arilo piperidinas como moduladores de monoacilglicerol lipasa. |
| US11505546B2 (en) | 2020-03-26 | 2022-11-22 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
| KR20230062555A (ko) | 2020-09-03 | 2023-05-09 | 에프. 호프만-라 로슈 아게 | 신규 헤테로사이클릭 화합물 |
| TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| JP2024518425A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| AU2022328310A1 (en) * | 2021-08-09 | 2024-03-28 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibition of monoacylglycerol lipase (MAGL) |
| WO2023160004A1 (zh) * | 2022-02-25 | 2023-08-31 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483228B1 (en) * | 2002-03-13 | 2010-06-02 | Schering Corporation | Nk1 antagonists |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| TWI465446B (zh) | 2009-04-22 | 2014-12-21 | Janssen Pharmaceutica Nv | 作為單醯基甘油脂酶抑制劑之吖丁啶基二醯胺類（四） |
| WO2010124122A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| BRPI1014888A2 (pt) | 2009-04-22 | 2019-09-24 | Janssen Pharmaceutica Nv | piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase |
| WO2011044197A1 (en) * | 2009-10-07 | 2011-04-14 | Bristol-Myers Squibb Company | Spirocyclic compounds as modulators of chemokine receptor activity |
| AU2011296068B2 (en) | 2010-09-03 | 2015-07-09 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
| CN103080103A (zh) | 2010-09-27 | 2013-05-01 | 詹森药业有限公司 | 作为单酰甘油脂肪酶抑制剂的氧代哌嗪-氮杂环丁烷酰胺和氧代二氮杂*-氮杂环丁烷酰胺 |
| CA2815350A1 (en) * | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| WO2013049289A1 (en) | 2011-09-30 | 2013-04-04 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
| WO2013049293A1 (en) | 2011-09-30 | 2013-04-04 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
| KR101653473B1 (ko) * | 2012-01-06 | 2016-09-01 | 어바이드 테라퓨틱스, 인크. | 카르바메이트 화합물 및 그의 제조 및 이용 방법 |
| JP6454349B2 (ja) | 2013-12-26 | 2019-01-16 | 武田薬品工業株式会社 | モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤としての４−（ピペラジン−１−イル）−ピロリジン−２−オン化合物 |
| WO2015106058A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Patent Gmbh | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
| US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2017
- 2017-03-30 TN TNP/2018/000299A patent/TN2018000299A1/en unknown
- 2017-03-30 CN CN201780032516.6A patent/CN109715613B/zh active Active
- 2017-03-30 UA UAA201810731A patent/UA122435C2/uk unknown
- 2017-03-30 SG SG11201807539UA patent/SG11201807539UA/en unknown
- 2017-03-30 JP JP2018549603A patent/JP6788683B2/ja active Active
- 2017-03-30 BR BR112018068538-0A patent/BR112018068538B1/pt active IP Right Grant
- 2017-03-30 CA CA3019298A patent/CA3019298C/en active Active
- 2017-03-30 EP EP17723531.4A patent/EP3436444B1/en active Active
- 2017-03-30 WO PCT/JP2017/014597 patent/WO2017171100A1/en not_active Ceased
- 2017-03-30 PL PL17723531T patent/PL3436444T3/pl unknown
- 2017-03-30 EA EA201892215A patent/EA036637B1/ru not_active IP Right Cessation
- 2017-03-30 KR KR1020187030584A patent/KR102388440B1/ko active Active
- 2017-03-30 MY MYPI2018703541A patent/MY194647A/en unknown
- 2017-03-30 AR ARP170100789A patent/AR108012A1/es active IP Right Grant
- 2017-03-30 US US15/474,192 patent/US10323026B2/en active Active
- 2017-03-30 DK DK17723531.4T patent/DK3436444T3/da active
- 2017-03-30 PE PE2018001848A patent/PE20190409A1/es unknown
- 2017-03-30 TW TW106110783A patent/TWI738753B/zh active
- 2017-03-30 UY UY0001037174A patent/UY37174A/es not_active Application Discontinuation
- 2017-03-30 MX MX2018011729A patent/MX374833B/es active IP Right Grant
- 2017-03-30 ES ES17723531T patent/ES2804580T3/es active Active
- 2017-03-30 AU AU2017245125A patent/AU2017245125B2/en active Active
-
2018
- 2018-08-30 IL IL261488A patent/IL261488B/en active IP Right Grant
- 2018-09-13 CO CONC2018/0009604A patent/CO2018009604A2/es unknown
- 2018-09-28 PH PH12018502101A patent/PH12018502101A1/en unknown
- 2018-09-28 CL CL2018002777A patent/CL2018002777A1/es unknown
- 2018-10-30 ZA ZA2018/07249A patent/ZA201807249B/en unknown
- 2018-10-30 EC ECSENADI201881909A patent/ECSP18081909A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068538A2 (pt) | composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. | |
| CO2020003932A2 (es) | Compuesto heterocíclico | |
| CO2018000858A2 (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl | |
| UY36071A (es) | Compuesto de ciclopropanamina y sus usos | |
| CO2019006785A2 (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| BR112022005595A2 (pt) | Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto | |
| BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
| BR112016024472A8 (pt) | composto, medicamento, e, uso de um composto | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CR20160348A (es) | Compuestos | |
| BR112014025711A8 (pt) | composto, medicamento, e, uso de um composto | |
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
| ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112020022088A8 (pt) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| BR112014010868A8 (pt) | composto de fórmula (i), composição de extrato de withania somnifera, composição de extrato de ws, composição farmacêutica ou nutracêutica, método de produção de uma composição de extrato de withania somnifera (ws), método de produção de um composto de fórmula (i) e uso de uma quantidade efetiva do composto | |
| MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
| BR112017023818A2 (pt) | composto, medicamento, métodos para inibição do receptor 4 do tipo toll em um mamífero e para profilaxia ou tratamento de uma doença ou condição, e, uso de um composto ou sal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2017, OBSERVADAS AS CONDICOES LEGAIS |